Long-Term Follow-up Study
Launched by CARIBOU BIOSCIENCES, INC. · Apr 14, 2022
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This is an observational, non-interventional, LTFS of investigational Caribou therapies in patients who have participated in a parent study: a prior Caribou-sponsored clinical study, special access program, or an IIT. The objective is to evaluate the long-term safety, through 15 years post infusion, in patients who received IPs in a Caribou-sponsored clinical study, special access program or IIT.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Written informed consent (by patient or legal representative) obtained prior to study-specific activities/enrollment
- • Completed a Caribou-sponsored study or was administered Caribou IP under a special access program or as part of an IIT
- • Use of an effective method of birth control by women of childbearing potential and their partners and men with partners of childbearing potential (partners must also use an effective birth control method) through 12 months post IP infusion.
- Exclusion Criteria:
- • None
About Caribou Biosciences, Inc.
Caribou Biosciences, Inc. is a leading biotechnology company focused on harnessing the power of CRISPR gene-editing technology to advance innovative therapeutics for a range of diseases. With a commitment to transforming the landscape of genetic medicine, Caribou is dedicated to developing next-generation cell therapies and genomic medicines that address unmet medical needs. The company's robust pipeline includes programs targeting cancer and other serious conditions, leveraging its proprietary CRISPR platform to create precise, effective, and safe treatment options. Through rigorous scientific research and collaboration, Caribou Biosciences aims to drive breakthroughs that improve patient outcomes and enhance the quality of life for individuals affected by complex diseases.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Lexington, Kentucky, United States
Milwaukee, Wisconsin, United States
Bronx, New York, United States
La Jolla, California, United States
Cleveland, Ohio, United States
Birmingham, Alabama, United States
Houston, Texas, United States
Denver, Colorado, United States
Dallas, Texas, United States
Seattle, Washington, United States
Denver, Colorado, United States
Cincinnati, Ohio, United States
Louisville, Kentucky, United States
Richmond, Virginia, United States
Iowa City, Iowa, United States
Salt Lake City, Utah, United States
Atlanta, Georgia, United States
New York, New York, United States
Gilbert, Arizona, United States
New York, New York, United States
Scottsdale, Arizona, United States
Irvine, California, United States
Orlando, Florida, United States
Augusta, Georgia, United States
Morristown, New Jersey, United States
Nashville, Tennessee, United States
Hackensack, New Jersey, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials